David Bejker
President and Chief Executive Officer
Employed since 2008.
Born: 1975
David Bejker has an extensive background in the biotechnology industry, both as investor and business developer. He has previous experience from the venture capital firm HealthCap. He is Board Director at Affibody AB, Amylonix AB, Disruptive Pharma Holding AB, Abliva AB, and Abliva Incentive AB. David holds a MSc degree in Business Administration from the Stockholm School of Economics, where he was awarded the Karl-Adam Bonnier Scholarship to Darden Graduate Business School, Charlotteville, Virginia.
Holdings in Affibody: 43,000 shares (including related natural parties) and 200,000 options.
Karin Nord
SVP Research Operations
Employed since 2000.
Born: 1969
Karin Nord is one of Affibody’s co-founders and was one of the company’s first employees. She received her PhD, which included pioneering research on Affibody® molecules, from KTH Royal Institute of Technology, Stockholm, in 1999. Additionally, she holds has an MSc in chemistry from Karlstad University. Karin was the main author of the first scientific article concerning Affibody® molecules, which was published in Nature Biotechnology in 1997
Holdings in Affibody: 67,805 shares (including related natural parties) and 75,000 options.
Fredrik Frejd
Chief Scientific Officer
Employed since 2002.
Born: 1973
Fredrik Frejd has over 20 years of experience in biomedical research with expertise in tumor biology, biotechnological phage display, and therapeutic protein technique with antibody fragments, as well as artificial scaffold proteins. Fredrik is an adjunct Professor at the Department of Cancer Precision Medicine at Uppsala University. He is a Board Director of Mergus development AB, Akiram Therapeutics AB, Immuneed AB, and Deputy Board Director of Amylonix AB. Fredrik is also a member of Technische Universität Dresden Center for Molecular Bioengineering’s scientific council.
Holdings in Affibody: 29,446 shares (including related natural parties) and 75,000 options.
Nikolai Brun
Chief Medical Officer
Employed since 2021.
Born: 1966
Nikolai Brun has 20 years of experience in the life science industry, including deep expertise in clinical drug development, regulatory affairs, and medical affairs. Previous to his position at Affibody, he held the position of Chief Medical Officer at the Danish Medical Agency. Additionally, he has held leading positions at Novo Nordisk, Genmab, and Genzyme. Nikolai holds a medical degree and a PhD from the University of Copenhagen.
Holdings in Affibody: 75,000 options.
Peter Zerhouni
Chief Financial Officer and Chief Business Officer
Employed since 2023.
Born: 1972
Peter Zerhouni has more than 15 years of experience from executive positions in listed biotechnology companies in clinical development stage. He has previously been Chief Executive Officer of InDex Pharmaceuticals and Diamyd Medical. Peter holds a MSc degree in biology as well as a BSc degree in business administration and economics from Lund University, and he has also studied at University of California at Berkeley.
Holdings in Affibody: 75,000 options.